Atrinsic Inc. (NASDAQ:PTIX – Get Free Report)’s stock price was up 10.9% during trading on Tuesday . The company traded as high as $0.50 and last traded at $0.50. Approximately 2,974 shares traded hands during trading, a decline of 96% from the average daily volume of 77,387 shares. The stock had previously closed at $0.4507.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Atrinsic in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
Read Our Latest Report on PTIX
Atrinsic Price Performance
Atrinsic Company Profile
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.
Featured Stories
- Five stocks we like better than Atrinsic
- New Copper-Rich “Kraken” Zone Discovered
- Silver Is the New Oil—And the World’s Running Dry
- America’s 1776 happening again
- 3 Signs You May Want to Switch Financial Advisors
- Silver’s squeeze is tightening – opportunity forming
Receive News & Ratings for Atrinsic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrinsic and related companies with MarketBeat.com's FREE daily email newsletter.
